Table 1 Baseline characteristic of MPZ group (n = 7) and IVCY group (n = 13)
| Â | MPZ group (n = 7) | IVCY group (n = 13) | P value* |
|---|---|---|---|
First case/recurrence case, n (%) | 6 (85.7)/1 (14.3) | 12 (92.3)/1 (7.7) | 1.0000 |
Male/female | 3/4 | 4/9 | 0.6514 |
Age | 74.0 (63.0, 83.0) | 60.0 (56.0, 76.5) | 0.2042 |
Disease duration (months) | 0 (0, 1) | 0 (0, 0) | 0.5327 |
Concomitant CS dose (PSL mg/day) | 50.0 (50.0, 70.0) | 60.0 (40.0, 65.0) | 0.9362 |
BVAS | 17.0 (14.0, 24.0) | 17.0 (13.5, 22.5) | 0.9051 |
BVAS items | |||
 General | 6 (85.7) | 11 (84.6) | 1.0000 |
 Cutaneous | 5 (71.4) | 9 (69.2) | 1.0000 |
 ENT | 5 (71.4) | 7 (53.8) | 0.6424 |
 Cardiomyopathy | 1 (14.3) | 2 (15.4) | 1.0000 |
 Chest | 5 (71.4) | 8 (61.5) | 1.0000 |
 Abdominal | 1 (14.3) | 1 (7.7) | 1.0000 |
 Renal | 2 (28.6) | 3 (23.1) | 1.0000 |
 Sensory neuropathy | 5 (71.4) | 12 (92.3) | 0.2702 |
 Motor neuropathy | 2 (28.6) | 6 (46.2) | 0.6424 |
 ANCA positive status, n (%) | 2 (28.6) | 2 (15.4) | 0.5868 |
 White blood cell count (/μL) | 15,200 (12,500, 25,500) | 16,600 (14,650, 21,550) | 0.4511 |
 Absolute eosinophil count (/μL) | 5760 (2475, 15,478) | 7434 (1881, 11,273) | 0.7214 |
 CRP (mg/dL) | 3.72 (0.80, 10.1) | 8.50 (1.20, 13.9) | 0.4054 |
 ESR (mm/h) | 44.0 (33.0, 78.0) | 52.0 (23.0, 79.0) | 0.8740 |
 IgE (IU/mL) | 997 (253, 1971) | 1112 (436.5, 3586.5) | 0.5006 |